Display options
Cite
Zastrozhin MS, Skryabin VY, Miroshkin SS, et al. Pharmacogenetics of alcohol addiction: current perspectives. Appl Clin Genet. 2019;12:131-140doi: 10.2147/TACG.S206745.
Zastrozhin, M. S., Skryabin, V. Y., Miroshkin, S. S., Bryun, E. A., & Sychev, D. A. (2019). Pharmacogenetics of alcohol addiction: current perspectives. The application of clinical genetics, 12131-140. https://doi.org/10.2147/TACG.S206745
Zastrozhin, M S, et al. "Pharmacogenetics of alcohol addiction: current perspectives." The application of clinical genetics vol. 12 (2019): 131-140. doi: https://doi.org/10.2147/TACG.S206745
Zastrozhin MS, Skryabin VY, Miroshkin SS, Bryun EA, Sychev DA. Pharmacogenetics of alcohol addiction: current perspectives. Appl Clin Genet. 2019 Jul 11;12:131-140. doi: 10.2147/TACG.S206745. eCollection 2019. PMID: 31372024; PMCID: PMC6628972.
Copy Download .nbib Format: NLM
Share it on

Appl Clin Genet. 2019 Jul 11;12:131-140. doi: 10.2147/TACG.S206745. eCollection 2019.

Pharmacogenetics of alcohol addiction: current perspectives.

The application of clinical genetics

M S Zastrozhin, V Yu Skryabin, S S Miroshkin, E A Bryun, D A Sychev

Affiliations

  1. Moscow Research and Practical Centre on Addictions of the Moscow Department of Healthcare , Moscow 109390, Russian Federation.
  2. Department of Addictology, Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, Moscow 123995, Russian Federation.

PMID: 31372024 PMCID: PMC6628972 DOI: 10.2147/TACG.S206745

Abstract

Genetics of alcohol addiction is currently a contradictive and complex field, where data in the most studies reflect methods' limitations rather than meaningful and complementary results. In our review, we focus on the genetics of alcohol addiction, leaving genetics of acute alcohol intoxication out of the scope. A review of the literature on pharmacogenetic biomarkers development for the pharmacotherapy personalization reveals that today the evidence base concerning these biomarkers is still insufficient. In particular, now the researches with the design of randomized controlled trials and meta-analysis investigating the effect of the SNPs as biomarkers on the therapy efficacy are available for naltrexone only. For other medications, there are only a few studies in small samples. It decreases the possibilities to implement the pharmacogenetic algorithms for the pharmacotherapy personalization in patients with alcohol use disorders (AUD). In view of the importance of the precision approaches development not in addiction medicine only, but in other fields of medicine also to increase the efficacy and safety of the therapy, studies on pharmacogenetic biomarkers development for the medications used in patients with AUD (eg, naltrexone, disulfiram, nalmefene, acamprosate, etc.) remain relevant to this day.

Keywords: acamprosate; alcohol use disorder; nalmefene; naltrexone; pharmacogenetics; pharmacogenomics

Conflict of interest statement

The authors report no conflicts of interest in this work.

References

  1. Mol Psychiatry. 1999 Sep;4(5):476-83 - PubMed
  2. Clin Pharmacol Ther. 1999 Dec;66(6):642-6 - PubMed
  3. Epilepsia. 2000;41 Suppl 1:S17-20 - PubMed
  4. JAMA. 2000 Aug 23-30;284(8):963-71 - PubMed
  5. J Abnorm Psychol. 2000 Nov;109(4):738-42 - PubMed
  6. Curr Psychiatry Rep. 2001 Apr;3(2):144-51 - PubMed
  7. Can J Physiol Pharmacol. 2001 Aug;79(8):673-81 - PubMed
  8. Alcohol Clin Exp Res. 2001 Sep;25(9):1335-41 - PubMed
  9. Pharmacogenomics J. 2001;1(2):152-6 - PubMed
  10. Neuroreport. 2003 Mar 24;14(4):569-72 - PubMed
  11. Lancet. 2003 May 17;361(9370):1677-85 - PubMed
  12. Neuropsychopharmacology. 2003 Aug;28(8):1546-52 - PubMed
  13. Alcohol Clin Exp Res. 2003 Jul;27(7):1150-5 - PubMed
  14. Acta Psychiatr Scand Suppl. 1992;369:7-13 - PubMed
  15. Clin Pharmacol Ther. 1992 Aug;52(2):160-9 - PubMed
  16. Psychopharmacology (Berl). 2004 Aug;174(4):463-76 - PubMed
  17. Addiction. 2004 Jul;99(7):811-28 - PubMed
  18. Arch Intern Med. 2004 Jul 12;164(13):1405-12 - PubMed
  19. Alcohol Clin Exp Res. 2004 Sep;28(9):1356-61 - PubMed
  20. N Engl J Med. 2005 Feb 10;352(6):596-607 - PubMed
  21. Drug Alcohol Depend. 2005 Apr 4;78(1):1-22 - PubMed
  22. Clin Pharmacol Ther. 2005 May;77(5):373-87 - PubMed
  23. Nat Rev Genet. 2005 Jul;6(7):521-32 - PubMed
  24. Clin Pharmacol Ther. 2005 Dec;78(6):647-55 - PubMed
  25. Drug Metab Dispos. 2006 Mar;34(3):449-56 - PubMed
  26. Drug Metab Dispos. 2006 Jul;34(7):1198-207 - PubMed
  27. Drug Metab Dispos. 2006 Aug;34(8):1277-82 - PubMed
  28. Clin Pharmacol Ther. 2006 Jun;79(6):590-9 - PubMed
  29. Alcohol Clin Exp Res. 2006 Aug;30(8):1288-96 - PubMed
  30. J Clin Psychopharmacol. 2007 Feb;27(1):112-5 - PubMed
  31. Alcohol Clin Exp Res. 2007 Apr;31(4):555-63 - PubMed
  32. J Clin Pharm Ther. 2007 Aug;32(4):333-41 - PubMed
  33. JAMA. 2007 Oct 10;298(14):1641-51 - PubMed
  34. Expert Rev Neurother. 2007 Oct;7(10):1265-77 - PubMed
  35. Alcohol Clin Exp Res. 2008 Mar;32(3):489-97 - PubMed
  36. Arch Gen Psychiatry. 2008 Feb;65(2):135-44 - PubMed
  37. Psychopharmacology (Berl). 2009 Jan;201(4):611-8 - PubMed
  38. Xenobiotica. 2009 Feb;39(2):140-7 - PubMed
  39. Exp Clin Psychopharmacol. 2009 Apr;17(2):122-9 - PubMed
  40. Addict Biol. 2009 Jul;14(3):328-37 - PubMed
  41. Pharmacol Rev. 2010 Mar;62(1):97-135 - PubMed
  42. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):5-12 - PubMed
  43. Curr Pharm Des. 2010;16(19):2141-8 - PubMed
  44. Pharmacogenomics J. 2011 Oct;11(5):368-74 - PubMed
  45. Cochrane Database Syst Rev. 2010 Dec 08;(12):CD001867 - PubMed
  46. Am J Psychiatry. 2011 Mar;168(3):265-75 - PubMed
  47. Alcohol Clin Exp Res. 2011 Jun;35(6):1134-41 - PubMed
  48. Clin Pharmacol Ther. 2011 Aug;90(2):328-32 - PubMed
  49. Pharmacogenet Genomics. 2011 Dec;21(12):902-5 - PubMed
  50. Pharmacogenet Genomics. 2012 Feb;22(2):159-65 - PubMed
  51. Clin Pharmacol Ther. 1990 Nov;48(5):496-502 - PubMed
  52. Addict Biol. 2012 May;17(3):505-12 - PubMed
  53. Alcohol Clin Exp Res. 2012 Nov;36(11):2000-7 - PubMed
  54. J Clin Psychopharmacol. 2012 Aug;32(4):578-80 - PubMed
  55. Addict Biol. 2013 Jan;18(1):193-201 - PubMed
  56. Pharmacol Biochem Behav. 2012 Dec;103(2):253-9 - PubMed
  57. Neuropsychopharmacology. 2013 Feb;38(3):414-22 - PubMed
  58. Br J Clin Pharmacol. 2014 Feb;77(2):315-23 - PubMed
  59. Biol Psychiatry. 2013 Apr 15;73(8):700-1 - PubMed
  60. Eur Neuropsychopharmacol. 2013 Nov;23(11):1432-42 - PubMed
  61. Pharmacogenet Genomics. 2013 Jul;23(7):333-40 - PubMed
  62. Curr Opin Neurobiol. 2013 Aug;23(4):692-9 - PubMed
  63. Am J Psychiatry. 2013 Sep;170(9):1020-31 - PubMed
  64. Eur Neuropsychopharmacol. 2014 Feb;24(2):181-91 - PubMed
  65. JAMA Intern Med. 2014 Jan;174(1):70-7 - PubMed
  66. Biol Psychiatry. 2014 May 15;75(10):790-7 - PubMed
  67. Alcohol Alcohol. 2014 May-Jun;49(3):261-70 - PubMed
  68. PLoS One. 2014 Feb 10;9(2):e87366 - PubMed
  69. ACS Chem Neurosci. 2014 Apr 16;5(4):253-60 - PubMed
  70. J Alcohol Drug Depend. 2013 Jan 1;1(1):101 - PubMed
  71. CNS Drugs. 2014 May;28(5):401-10 - PubMed
  72. Int J Neuropsychopharmacol. 2014 Oct;17(10):1549-56 - PubMed
  73. Alcohol Clin Exp Res. 2014 Jun;38(6):1481-8 - PubMed
  74. JAMA. 2014 May 14;311(18):1889-900 - PubMed
  75. Transl Psychiatry. 2014 Oct 07;4:e462 - PubMed
  76. Pharmacogenomics. 2014 Sep;15(13):1687-700 - PubMed
  77. N Engl J Med. 2014 Nov 27;371(22):2109-13 - PubMed
  78. J Clin Psychopharmacol. 2015 Feb;35(1):34-42 - PubMed
  79. Malar J. 2014 Dec 04;13:478 - PubMed
  80. Addict Biol. 2016 Mar;21(2):450-9 - PubMed
  81. Biopharm Drug Dispos. 2015 May;36(4):258-64 - PubMed
  82. Adicciones. 2014;26(4):360-70 - PubMed
  83. Drugs. 2015 Mar;75(4):353-65 - PubMed
  84. Drug Metab Dispos. 2015 May;43(5):660-8 - PubMed
  85. JAMA Psychiatry. 2015 May;72(5):430-7 - PubMed
  86. Pharmacopsychiatry. 2015 Jul;48(4-5):123-35 - PubMed
  87. CNS Drugs. 2015 May;29(5):383-95 - PubMed
  88. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4 Pt 2):14-23 - PubMed
  89. Psychiatry Res. 2015 Dec 15;230(2):121-9 - PubMed
  90. Ther Drug Monit. 2017 Feb;39(1):55-61 - PubMed
  91. CNS Drugs. 2017 Feb;31(2):87-95 - PubMed
  92. Aliment Pharmacol Ther. 2017 Apr;45(7):865-882 - PubMed
  93. Pharmacogenomics. 2017 Apr;18(6):555-570 - PubMed
  94. Neuropsychopharmacology. 2017 Dec;42(13):2640-2653 - PubMed
  95. JAMA. 2017 Jun 13;317(22):2267-2269 - PubMed
  96. Expert Opin Pharmacother. 2017 Aug;18(12):1187-1199 - PubMed
  97. Addiction. 2018 Feb;113(2):220-237 - PubMed
  98. Expert Opin Drug Saf. 2018 Feb;17(2):169-177 - PubMed
  99. Am J Psychiatry. 2018 Jan 1;175(1):86-90 - PubMed
  100. Pharmacol Res. 2018 Jul;133:65-76 - PubMed
  101. Riv Psichiatr. 2018 May-Jun;53(3):123-127 - PubMed
  102. Eur Neuropsychopharmacol. 2018 Jul;28(7):795-806 - PubMed
  103. Ment Health Clin. 2018 Mar 23;7(3):106-110 - PubMed
  104. Adv Clin Exp Med. 2019 Feb;28(2):199-202 - PubMed
  105. J Addict Med. 2019 Jan/Feb;13(1):7-22 - PubMed
  106. Trials. 2018 Aug 16;19(1):443 - PubMed
  107. Neuropsychopharmacol Rep. 2018 Sep;38(3):105-116 - PubMed
  108. Am J Psychiatry. 1969 Jun;125(12):1640-6 - PubMed
  109. Br J Clin Pharmacol. 1996 Oct;42(4):471-4 - PubMed
  110. Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9608-13 - PubMed

Publication Types